Gamida France

Gamida France company information, Employees & Contact Information

Explore related pages

Related company profiles:

Acteur incontournable du marché français de l’Anesthésie Réanimation, la Chirurgie, le Biomédical et de l’Oncologie, Gamida fournit des produits, des formations, des services et des solutions thérapeutiques aux Hôpitaux, Cliniques et Prestataires de Santé à Domicile en France et Dom Tom. Nos partenaires nous font confiance, pour certains d’entre eux depuis plus de 30 ans, pour assurer la distribution de leurs produits en France. Après la livraison, notre engagement continu : les techniciens du Service Après-Vente GamidaTech, société sœur de Gamida, apportent à l’utilisateur et au technicien biomédical la garantie d’un véritable accompagnement pendant toute la durée de vie du produit.

Company Details

Employees
60
Founded
-
Address
31 Rue Des Alouettes, Eaubonne,95600,france
Industry
Wholesale
NAICS
Wholesale Trade
Merchant Wholesalers, Durable Goods
Merchant Wholesalers, Nondurable Goods
Office Equipment Merchant Wholesalers
Other Commercial Equipment Merchant Wholesalers
Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
Ophthalmic Goods Merchant Wholesalers
Other Professional Equipment and Supplies Merchant Wholesalers
Sporting and Recreational Goods and Supplies Merchant Wholesalers
Toy and Hobby Goods and Supplies Merchant Wholesalers
Other Miscellaneous Durable Goods Merchant Wholesalers
Farm Supplies Merchant Wholesalers
Book, Periodical, and Newspaper Merchant Wholesalers
Flower, Nursery Stock, and Florists' Supplies Merchant Wholesalers
Tobacco and Tobacco Product Merchant Wholesalers
Paint, Varnish, and Supplies Merchant Wholesalers
Other Miscellaneous Nondurable Goods Merchant Wholesalers
Professional and Commercial Equipment and Supplies Merchant Wholesalers
Website
gamida.fr
HQ
Eaubonne
Looking for a particular Gamida France employee's phone or email?

Gamida France Questions

News

BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell - Yahoo Finance

BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell Yahoo Finance

Unable to find a partner for stem cell therapy, Gamida accepts sale to investment firm to survive - Fierce Biotech

Unable to find a partner for stem cell therapy, Gamida accepts sale to investment firm to survive Fierce Biotech

Gamida Cell files for U.S. bankruptcy as it undergoes restructuring - The Business Journals

Gamida Cell files for U.S. bankruptcy as it undergoes restructuring The Business Journals

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd. - PR Newswire

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd. PR Newswire

Gamida Cell’s Omisirge Administered to First Patient in Commercial Setting - CGTLive®

Gamida Cell’s Omisirge Administered to First Patient in Commercial Setting CGTLive®

Gamida Cell shares crater after cell therapy maker announces private transition - FirstWord Pharma

Gamida Cell shares crater after cell therapy maker announces private transition FirstWord Pharma

After going all-in on blood cancer therapy, Gamida Cell scores big win at FDA - Fierce Pharma

After going all-in on blood cancer therapy, Gamida Cell scores big win at FDA Fierce Pharma

The first-quarter curtain falls on Pieris and Gamida | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

The first-quarter curtain falls on Pieris and Gamida | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Gamida Cell Secures World’s 1st FDA Approval for an Expanded Cord Blood Cell Therapy - BioInformant

Gamida Cell Secures World’s 1st FDA Approval for an Expanded Cord Blood Cell Therapy BioInformant

Gamida Cell Announces New Leadership Under Ownership of Highbridge Capital Management - Business Wire

Gamida Cell Announces New Leadership Under Ownership of Highbridge Capital Management Business Wire

Going private last option for Gamida Cell to remain as going concern - The Pharma Letter

Going private last option for Gamida Cell to remain as going concern The Pharma Letter

Gamida steps up search for 'strategic alternatives' despite stem cell therapy reaching market - Fierce Biotech

Gamida steps up search for 'strategic alternatives' despite stem cell therapy reaching market Fierce Biotech

Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual Meeting - Yahoo Finance

Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual Meeting Yahoo Finance

First Patient Dosed with Gamida Cell’s Expanded Cord Blood Cell Therapy, Omisirge™ - BioInformant

First Patient Dosed with Gamida Cell’s Expanded Cord Blood Cell Therapy, Omisirge™ BioInformant

Gamida Cell Announces Pricing of $23 Million Public Offering of Securities - Business Wire

Gamida Cell Announces Pricing of $23 Million Public Offering of Securities Business Wire

Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update - Yahoo Finance

Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update Yahoo Finance

Gamida Cell readies stem cell transplant therapy for FDA submission but seeks strategic partners amid staffing cuts - Fierce Biotech

Gamida Cell readies stem cell transplant therapy for FDA submission but seeks strategic partners amid staffing cuts Fierce Biotech

Gamida Cell (GMDA) Surges on FDA Approval for Omisirge - Yahoo Finance

Gamida Cell (GMDA) Surges on FDA Approval for Omisirge Yahoo Finance

Novartis-backed cell therapy startup Gamida files for IPO - Fierce Biotech

Novartis-backed cell therapy startup Gamida files for IPO Fierce Biotech

Gamida lays off 17%, ditches NK cell therapy work to keep blood cancer drug on track - Fierce Biotech

Gamida lays off 17%, ditches NK cell therapy work to keep blood cancer drug on track Fierce Biotech

Gamida restructuring deal to support Omisirge - BioProcess International

Gamida restructuring deal to support Omisirge BioProcess International

Gamida Restructures Under Ownership of Highbridge Capital Management - BioSpace

Gamida Restructures Under Ownership of Highbridge Capital Management BioSpace

Biotech Co. Gamida Gets OK For Prepack Ch. 11 Plan - Law360

Biotech Co. Gamida Gets OK For Prepack Ch. 11 Plan Law360

Gamida Cell Presents Positive Initial Results on Treating Severe Aplastic Anemia (SAA) with Omidubicel - BioSpace

Gamida Cell Presents Positive Initial Results on Treating Severe Aplastic Anemia (SAA) with Omidubicel BioSpace

Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update - GlobeNewswire

Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update GlobeNewswire

Gamida Cell and Be The Match BioTherapies® Expand Strategic Collaboration - BioInformant

Gamida Cell and Be The Match BioTherapies® Expand Strategic Collaboration BioInformant

Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer - Fierce Pharma

Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer Fierce Pharma

Gamida Cell wins FDA approval for new cord blood-based therapy for cancer patients - Endpoints News

Gamida Cell wins FDA approval for new cord blood-based therapy for cancer patients Endpoints News

Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies - Business Wire

Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies Business Wire

Priority review for Gamida's cell therapy; PhIII shuttered at Akari; Immutep drops data on LAG3 study - Endpoints News

Priority review for Gamida's cell therapy; PhIII shuttered at Akari; Immutep drops data on LAG3 study Endpoints News

Gamida Cell Appoints Vladimir Melnikov as Senior Vice President, Global Operations and Manufacturing - citybiz

Gamida Cell Appoints Vladimir Melnikov as Senior Vice President, Global Operations and Manufacturing citybiz

Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval - Business Wire

Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval Business Wire

Gamida Cell has a second chance to be an Israeli success story - The Jerusalem Post

Gamida Cell has a second chance to be an Israeli success story The Jerusalem Post

Gamida wins FDA approval for off-the-shelf cell therapy - BioProcess International

Gamida wins FDA approval for off-the-shelf cell therapy BioProcess International

Gamida Cell, President Dr. Yael Margolin Reveals the Unmet Need in HSCT - BioInformant

Gamida Cell, President Dr. Yael Margolin Reveals the Unmet Need in HSCT BioInformant

Gamida Cell and Be The Match BioTherapies® Expand Strategic Collaboration - Business Wire

Gamida Cell and Be The Match BioTherapies® Expand Strategic Collaboration Business Wire

Ascendis spins out ophthalmology company; Gamida Cell eyes strategic options - Endpoints News

Ascendis spins out ophthalmology company; Gamida Cell eyes strategic options Endpoints News

Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management - Stock Titan

Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management Stock Titan

Israel's Gamida Cell Survives By Selling To Lender - Citeline News & Insights

Israel's Gamida Cell Survives By Selling To Lender Citeline News & Insights

FDA & Gamida Cell Discuss BLA for Omidubicel in Blood Cancer Patients - NAVLIN DAILY

FDA & Gamida Cell Discuss BLA for Omidubicel in Blood Cancer Patients NAVLIN DAILY

Financial distress pushes key drug maker to Chapter 11 bankruptcy - TheStreet

Financial distress pushes key drug maker to Chapter 11 bankruptcy TheStreet

Novartis buys another 2.5 percent in Israel's Gamida Cell - Reuters

Novartis buys another 2.5 percent in Israel's Gamida Cell Reuters

Gamida Cell Presents Additional Positive Data of NiCord® in Blood Cancer Patients - BioInformant

Gamida Cell Presents Additional Positive Data of NiCord® in Blood Cancer Patients BioInformant

Cell therapy firm in flurry of activity as hope nears for bone marrow patients - The Times of Israel

Cell therapy firm in flurry of activity as hope nears for bone marrow patients The Times of Israel

Pharma Veteran Julian Adams takes Helm at Gamida Cell - CTech

Pharma Veteran Julian Adams takes Helm at Gamida Cell CTech

Gamida Cell, Novartis Sign Option Agreement - drugdiscoverytrends.com

Gamida Cell, Novartis Sign Option Agreement drugdiscoverytrends.com

Two Elbit Medical exit dreams punctured in a week - Globes - Israel Business News

Two Elbit Medical exit dreams punctured in a week Globes - Israel Business News

Gamida Cell to delist as Highbridge takes full ownership - Globes - Israel Business News

Gamida Cell to delist as Highbridge takes full ownership Globes - Israel Business News

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant